BioXcel stockholders approve reverse stock split authorization and elect directors

BioXcel Therapeutics, Inc.

All five proposals passed at Dec 12 annual meeting; 44.68% of shares voted.
Directors June Bray, Sandeep Laumas, David Mack elected as Class I directors.
Ernst & Young ratified as independent auditor for FY2025.
Advisory say-on-pay approved with ~78% of votes cast (excl. broker non-votes).
Stockholders authorized reverse stock split of 1:2 to 1:20 to regain Nasdaq bid price compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.